

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM461313

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BioPharma Secured Investments III Holdings Cayman LP		02/07/2018	Limited Partnership: CAYMAN ISLANDS
RECEIVING PARTY DATA			
Name:	NovoCure Limited		
Street Address:	Second Floor, No. 4 The Forum, Grenville Street		
City:	St. Helier		
State/Country:	JERSEY		
Postal Code:	JE2 4UF		
Entity Type:	Corporation: JERSEY		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	86437407	OPTUNE	
CORRESPONDENCE DATA			
Fax Number:	2149813400		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	214-981-3483		
Email:	dclark@sidley.com		
Correspondent Name:	DUSAN CLARK, ESQ.		
Address Line 1:	SIDLEY AUSTIN LLP		
Address Line 2:	2021 MCKINNEY AVE., SUITE 2000		
Address Line 4:	DALLAS, TEXAS 75201		
ATTORNEY DOCKET NUMBER:	55118-10220		
NAME OF SUBMITTER:	Dusan Clark		
SIGNATURE:	/Dusan Clark/		
DATE SIGNED:	02/07/2018		
Total Attachments: 3			
source=Biopharma_Novocure - Release of TM Security Interest (Compiled)#page1.tif			
source=Biopharma_Novocure - Release of TM Security Interest (Compiled)#page2.tif			

CH \$40.00 86437407

RELEASE TRADEMARK SECURITY INTEREST

THIS RELEASE OF TRADEMARK SECURITY INTEREST (this “Release”) is made as of February 7 2018, (“Effective Date”) by BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP, (the “Lender”), in favor of NOVOCURE LIMITED, (the “Grantor”). All terms not herein defined, have the meanings set forth in the Security Agreement and TM Agreement referenced below.

WHEREAS, Grantor and the Lender are parties to that certain Guaranty and Security Agreement dated as of January 30, 2015 (as may be amended, restated, supplemented or otherwise modified from time to time, the “Security Agreement”) executed in order to secure the prompt and complete payment, observance and performance of all of the Obligations in accordance with the terms and conditions of the various loan documents;

WHEREAS, pursuant to the Security Agreement, the Grantor was required to execute and deliver a Trademark Property Security Agreement dated as of January 30, 2015 (the “TM Agreement”) to the Lender for purposes of filing with the United States Patent and Trademark Office (“USPTO”);

WHEREAS, pursuant to the Security Agreement and TM Agreement, the Grantor granted to the Lender, among other Trademark Collateral as set forth therein, a continuing security interest in all of the Grantor’s right, title and interest, including goodwill in the trademarks, in, to and under the United States trademarks registrations and applications listed on the attached Schedule A (the “Trademarks”);

WHEREAS, the TM Agreement was recorded in the USPTO on February 2, 2015 at Reel/Frame 5451/0125; and

WHEREAS, the Lender wishes to release its security interest in the Trademark Collateral, including the Trademarks on Schedule A.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Lender hereby terminates, releases and discharges any security interest in and lien upon the Trademark Collateral, including the Trademarks on Schedule A, and assigns, transfers, and conveys to the Grantor any and all right, title or interest in, or to, the Trademark Collateral that the Lender may hold.

Lender agrees, at the Grantor’s expense, to take all further actions, and provide to the Grantor and its successors, assigns and legal representatives all such cooperation and assistance, including, without limitation, the execution and delivery of any and all further documents or other instruments, as the Grantor and its successors, assigns and legal representatives may reasonably request in order to confirm, effectuate or record this Release.


[Signature Page Follows]

IN WITNESS WHEREOF, the Lender has caused this Release to be executed
its duly authorized representative effective as of the Effective Date.

BIOPHARMA SECURED INVESTMENTS III
HOLDINGS CAYMAN LP,

By: Pharmakon Advisors, LP, its Investment
Manager

By: Pharmakon Management I, LLC, its General
Partner

By:  _____

Name: Pedro Gonzalez de Cosio

Title: managing member

SCHEDULE A

Trademarks

<u>Name of Entity</u>	<u>Country</u>	<u>Title</u>	<u>Filing Date/Issued Date</u>	<u>Status</u>	<u>Application/Registration No.</u>
NovoCure Limited	European Union	Optune	11/6/2014	Published	13436911
NovoCure Limited	Israel	Optune	11/9/2014	Pending	269517
NovoCure Limited	Japan	Optune	11/6/2014	Pending	2014-093406
NovoCure Limited	Switzerland	Optune	11/6/2014	Pending	63059/2014
NovoCure Limited	United States	Optune	10/28/2014	Pending	86/437,407

ACTIVE 228658797